The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Gilyarov M.Yu.

Cardiologist, M.D., Professor

That’s right!

Authors:

Gilyarov M.Yu.

More about the authors

Journal: Non Nocere. New Therapeutic Journal. 2024;(12): 38‑43

Read: 325 times

Buy for 300₽
Contact the author
Table of contents

To cite this article:

Gilyarov MYu. That’s right! Non Nocere. New Therapeutic Journal. 2024;(12):38‑43. (In Russ.)

 
ЭндоКард
 
МСФ на ЯМ
Использование инфографики авторами научных работ
Abstract:

Glucagon-like peptide receptor agonists – 1.

Authors:

Gilyarov M.Yu.

Cardiologist, M.D., Professor

Close metadata

References:

  1. Yao H, Zhang A, Li D, et al. Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis. BMJ. 2024 Jan 29;384: e076410. https://doi.org/10.1136/bmj-2023-076410
  2. Hu EH, Tsai ML, Lin Y, Chou TS, Chen TH. A Review and Meta-Analysis of the Safety and Efficacy of Using Glucagon-like Peptide-1 Receptor Agonists. Medicina (Kaunas). 2024 Feb 21;60(3):357.  https://doi.org/10.3390/medicina60030357
  3. Vahora I, Moparthi KP, Al Rushaidi MT, et al. Efficacy of Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists for Weight Loss Management in Non-Diabetic Patients. Cureus. 2024 Jul 21;16(7):e65050. https://doi.org/10.7759/cureus.65050
  4. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023 Dec 14;389(24):2221-2232. https://doi.org/10.1056/NEJMoa2307563
  5. Badve SV, Bilal A, Lee MMY, et al. Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol. 2024 Nov 25:S2213-8587(24)00271-7.  https://doi.org/10.1016/S2213-8587(24)00271-7
  6. Wong C, Lee MH, Yaow CYL, Chin YH, et al. Glucagon-Like Peptide-1 Receptor Agonists for Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: A Meta-Analysis. Front Endocrinol (Lausanne). 2021 Apr 2021;12:609110. https://doi.org/10.3389/fendo.2021.609110
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.